JM-20 administration to animals with lesion of the nigrostriatal dopamine pathway induced by 6-hydroxydopamine, partially reverses motor damage and oxidative stress
Our study provides the preclinical evidence to support the long-term neuroprotective potential of JM-20 in 6-OHDA hemiparkinson rat model, pointing out to its possible use as a disease-modifying agent in PD.
Authors
- Luis Arturo Fonseca-Fonseca (ORCID: https://orcid.org/0000-0001-6904-5854)
- Jeney Ramírez-Sánchez
- Sílvia Lima Costa (ORCID: https://orcid.org/0000-0002-8975-3871)
- Nancy Pavón Fuentes (ORCID: https://orcid.org/0000-0003-0998-8601)
- Yanier Núñez-Figueredo (ORCID: https://orcid.org/0000-0003-4893-1763)
- Abel Mondelo Rodríguez
- Víctor Diógenes Amaral da Silva (ORCID: https://orcid.org/0000-0001-8032-9663)
- Laura Reina Taño Portuondo (ORCID: https://orcid.org/0009-0004-8010-3428)
Institutions
- Universidade Federal da Bahia (BR)
- Autonomous University of Yucatán (MX)
- Centro de Investigación y Desarrollo (ES)
- Centro de Información y Desarrollo de la Mujer (BO)
- Centre d'Innovació i Desenvolupament Empresarial (ES)
- International Center of Neurologic Restoration (CU)
- Centro de Investigación y Desarrollo de medicamentos
Publication Details
- Journal
- Neurological Research
- Published
- 2025-04-11
- DOI
- https://doi.org/10.1080/01616412.2025.2490089
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00